Since Grifols closed its Biotest investment in April 2022, both companies have closely collaborated to increase the availability of plasma therapies for the benefit of patients
Workforce
2,300+
Donor plasma centers
33+
Immunology and Neurology
Hematology
Hepatology / Intensive Care
Innovation
Strategic projects advanced: 2
Fibrinogen
IgM (Trimodulin)